NONO Is a Negative Regulator of
SOX2
breast cancer
cancer stem cell
negative regulator
transcription factor
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
25
03
2020
revised:
28
04
2020
accepted:
29
04
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
12
2
2021
Statut:
ppublish
Résumé
Sex determining region Y (SRY)-box 2 (SOX2) is a transcription factor essential for the maintenance of proliferation and self-renewal of cancer stem cells and is associated with breast cancer initiation. Regulation of cancer stem cell plasticity by SOX2 requires both positive and negative SOX2 transcription factors, but the negative regulator is still largely unknown. SOX2 promoter-binding proteins were identified by liquid chromatography-mass spectrometry/mass spectrometry, luciferase assay, and chromatin immunoprecipitation. The effects of one such transcription factor on SOX2 expression was investigated by knockdown and overexpression experiments. Non-POU domain-containing octamer-binding protein (NONO) (also known as 54-kDa nuclear RNA-binding protein, P54NRB) was identified as a SOX2 promoter-binding protein and a negative regulator of SOX2 expression. Its activity was controlled by its coiled-coil domain and the C-terminal domain. These results suggest that NONO acts as a key regulator of SOX2 transcription through the repression of SOX2 promoter activity in breast cancer cells.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Sex determining region Y (SRY)-box 2 (SOX2) is a transcription factor essential for the maintenance of proliferation and self-renewal of cancer stem cells and is associated with breast cancer initiation. Regulation of cancer stem cell plasticity by SOX2 requires both positive and negative SOX2 transcription factors, but the negative regulator is still largely unknown.
MATERIALS AND METHODS
METHODS
SOX2 promoter-binding proteins were identified by liquid chromatography-mass spectrometry/mass spectrometry, luciferase assay, and chromatin immunoprecipitation. The effects of one such transcription factor on SOX2 expression was investigated by knockdown and overexpression experiments.
RESULTS
RESULTS
Non-POU domain-containing octamer-binding protein (NONO) (also known as 54-kDa nuclear RNA-binding protein, P54NRB) was identified as a SOX2 promoter-binding protein and a negative regulator of SOX2 expression. Its activity was controlled by its coiled-coil domain and the C-terminal domain.
CONCLUSION
CONCLUSIONS
These results suggest that NONO acts as a key regulator of SOX2 transcription through the repression of SOX2 promoter activity in breast cancer cells.
Identifiants
pubmed: 32576581
pii: 17/4/359
doi: 10.21873/cgp.20195
pmc: PMC7367599
doi:
Substances chimiques
Biomarkers, Tumor
0
DNA-Binding Proteins
0
NONO protein, human
0
RNA-Binding Proteins
0
SOX2 protein, human
0
SOXB1 Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-367Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Mol Cell Biol. 2001 Apr;21(7):2298-311
pubmed: 11259580
Invest Ophthalmol Vis Sci. 2013 Jun 12;54(6):4007-15
pubmed: 23640037
BMC Cancer. 2001;1:15
pubmed: 11710964
J Clin Invest. 2008 Sep;118(9):3098-108
pubmed: 18677406
Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):4846-50
pubmed: 22416126
Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1204-8
pubmed: 18518878
Semin Cancer Biol. 2019 Mar 23;:
pubmed: 30914279
BMC Cancer. 2011 Jan 28;11:42
pubmed: 21276239
J Cell Physiol. 2018 May;233(5):4338-4344
pubmed: 29150959
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2525-30
pubmed: 19188602
Biochem Biophys Res Commun. 2013 Jul 26;437(2):205-11
pubmed: 23796710
Cell Death Dis. 2019 Aug 9;10(8):603
pubmed: 31399556
Hum Mol Genet. 2017 Jun 1;26(11):2042-2052
pubmed: 28334947
Mol Cell Endocrinol. 2012 Jun 24;357(1-2):18-29
pubmed: 21952082
Semin Cancer Biol. 2018 Dec;53:48-58
pubmed: 30130663
FEBS Lett. 2002 Nov 6;531(2):109-14
pubmed: 12417296
Oncogene. 2012 Mar 15;31(11):1354-65
pubmed: 21822303
Oncogene. 2016 Mar 17;35(11):1399-410
pubmed: 26148231
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):17976-81
pubmed: 15608055
Mol Endocrinol. 2009 Aug;23(8):1147-60
pubmed: 19423654
Mol Cell Biol. 1993 Sep;13(9):5593-603
pubmed: 8355702
PLoS One. 2019 Jul 31;14(7):e0215494
pubmed: 31365524
Cell Rep. 2016 Oct 18;17(4):997-1007
pubmed: 27760330
Oncotarget. 2015 Apr 30;6(12):10366-73
pubmed: 25868977
Oncogene. 2019 Mar;38(10):1764-1777
pubmed: 30382189